James D. Swanson $JNJ SEC Form 4 Insider Trading

James D. Swanson has filed a total of 4 insider trades in $JNJ since 2021. Their most recent trade was a sale of 19,368 shares, made on Feb 13, 2026. Their largest trade was a sale of 22,191 shares, made on Feb 13, 2026. We estimate that they now own 25,698 shares of $JNJ, worth an estimated $6.2 million.

Insider Trading at $JNJ

There have been a total of 373 insider trades reported at $JNJ since 2021, with 2,250 shares purchased and 1.2 million shares sold. The most active insider traders in $JNJ stock have been Peter Fasolo, Thibaut Mongon, and William Hait. The most recent trade was a sale of 4,075 shares reported by Robert J Decker (VP Corporate Controller), made on Feb 27, 2026.

$JNJ Executives and Stock Owners with Insider Trades

• Peter Fasolo, Exec VP, Chief HR Officer

• Thibaut Mongon, Exec VP, WW Chair, Consumer

• William Hait, See Remarks

• Joseph J Wolk, Exec VP, CFO

• John C Reed, EVP, Innovative Medicine, R&D

• Kathryn E Wengel, EVP, Chief GSC Officer

• Timothy Schmid, EVP, WW Chair, MedTech

• Joaquin Duato, CEO and Chairman of the Board

• Robert J Decker, Controller, CAO

• Robert J Decker, VP Corporate Controller

• James D. Swanson, EVP, CIO

• Jennifer L Taubert, EVP, WW Chair, Pharmaceuticals

• Vanessa Broadhurst, EVP, Global Corp Affairs

• Ashley Mcevoy, EVP, WW Chair, MedTech

• Jennifer L Taubert, EVP, WWC. Innovative Medicine

• Kathryn E Wengel, EVP, Chief TO and Risk Officer

• James D. Swanson, See Remarks

*This is only based off of information found in SEC filings, and may not reflect actual net worth. There may also be inaccuracies due to privately holdings filing errors, parsing errors, accidental double-counting of shares, incorrect classification of indirectly owned shares, sales prior to dataset start date, or any other number of issues.